Kenvue reports third quarter 2026 sales growth
Net sales rose 3.2% to $3.886 billion, organic sales grew 2.9%, and diluted EPS increased 5% to $0.22.
See the latest news and media coverage for Kenvue. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global consumer health company
kenvue.comLast updated
In short: Kenvue advanced its pending $48.7 billion Kimberly-Clark acquisition through key regulatory approvals and reported higher quarterly earnings.
Net sales rose 3.2% to $3.886 billion, organic sales grew 2.9%, and diluted EPS increased 5% to $0.22.
The board declared the dividend payable on October 2, 2026 to shareholders of record as of September 21.
Net sales rose 3.0% to $3.96 billion with diluted EPS of $0.24. The company also secured FDA approval for Tylenol with Naproxen.
The court remanded the case for further review of expert testimony. Kenvue maintains that science shows no link between acetaminophen and autism or ADHD.
Kenvue will be delisted as its $40 billion sale to Kimberly-Clark closes.
Kenvue Inc. reported earnings results for the third quarter and nine months ended September 27, 2026. For the third quarter, the company reported sales was...
The European Commission on Tuesday approved Kimberly-Clark 's acquisition of Tylenol maker Kenvue ...
Kenvue reported second-quarter 2026 revenue of USD 3.955 billion on August 6, 2026, an increase of 3.0 percent from the same quarter a year earlier...
Track Kenvue and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kenvue and other trending companies.